Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNCWXZ)

Drug Name

1,3,5-BENZENETRICARBOXYLIC ACID Drug Info

Synonyms

Trimesic acid; 554-95-0; 1,3,5-BENZENETRICARBOXYLIC ACID; benzene-1,3,5-tricarboxylic acid; Trimesinic acid; Trimesitinic acid; 5-Carboxyisophthalic acid; 1,3,5-Benzene tricarboxylic acid; 1,3,5-Tricarboxybenzene; UNII-OU36OO5MTN; NSC 3998; EINECS 209-077-7; OU36OO5MTN; CHEMBL77562; AI3-06468; CHEBI:46032; QMKYBPDZANOJGF-UHFFFAOYSA-N; MFCD00002517; Trimesicacid; 1,3,5-Benzenetricarboxylic acid, 98%; 1.3.5-Benzenetricarboxylic Acid; H3BTCt; Trimesic acid, 95%; 1,5-Tricarboxybenzene; PubChem18615; H3TMA; AC1Q1GOL; DSSTox_CID_1488

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11138
ChEBI ID: CHEBI:46032
CAS Number: CAS 554-95-0
TTD Drug ID: DMNCWXZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hemoglobin (HB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voxelotor	DMCS6M5	Sickle-cell disorder	3A51	Approved	[2]
Iron	DMAP8MV	Anemia of prematurity		Approved	[3]
Iron Dextran	DM5OY70	Iron-deficiency anemia	3A00	Approved	[3]
PolyHeme	DMV8EXG	Blood forming organ disorder	JB64.1	Phase 3	[4]
Efaproxyn	DMX7BM4	Lung cancer	2C25.0	Phase 3	[5]
Hemoglobin raffimer	DMMTL7V	Anemia	3A00-3A9Z	Phase 2/3	[6]
GBT021601	DMD3C21	Sickle-cell disorder	3A51	Phase 2/3	[7]
FBS-0701	DMR3952	Iron overload disease	5C64.10	Phase 2	[8]
HQK-1001	DM7QUN0	Beta thalassemia	3A50.2	Phase 2	[9]
5-hydroxymethyl-2-furfural	DMPFVJB	Anemia	3A00-3A9Z	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3	Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
4	Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
5	Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
6	Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
7	GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.
8	A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
9	A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
10	5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.